Navigation Links
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Date:9/21/2007

SAN CARLOS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX) announced today that it has completed enrollment in study C119, a second Phase 3 clinical trial of its lead product candidate NGX-4010 for the treatment of painful HIV-distal sensory polyneuropathy (HIV-DSP). NGX-4010 is a dermal patch designed to manage peripheral neuropathic pain. Previously completed Phase 3 trials demonstrated that a single, 30- or 60-minute treatment with NGX-4010 applied directly to the site of pain may provide pain relief for up to three months. C119 is a randomized, double-blind, controlled study that has enrolled over 480 patients at study sites in the United States, the United Kingdom, Australia and Canada.

"We believe that completion of enrollment in our C119 study marks a significant milestone in our NGX-4010 development program in HIV-DSP. We are currently in the follow-up phase of the study and expect to be able to provide top-line results near the end of the first quarter of 2008," commented Dr. Jeffery Tobias, Chief Medical Officer. "HIV-DSP is an important and underserved problem in patients with HIV/AIDS. There are currently no approved therapies for this indication. With the completion of enrollment in study C119, we are moving closer to our goal of providing an effective treatment for this patient population."

The study protocol for study C119 evaluates the effect of a single, 30- or 60-minute treatment with NGX-4010 or a low-concentration control patch applied directly to the patient's site of pain. NGX-4010 is administered by a physician during an in-office procedure. After 30 or 60 minutes, the study patch is removed and the patient's response to treatment is evaluated during the su
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
(Date:10/17/2014)... KIRKLAND, Wash. , Oct. 17, 2014  Talyst, ... at the 2014 LeadingAge Annual Meeting in ... its InSite System, the market leading solution for onsite, ... enables long term care facilities to safely and securely ... on time to first dose, helps ensure that the ...
(Date:10/17/2014)... 17, 2014   InnFocus, Inc ., reported on results ... States for up to 3 years with the ... in Chicago . The Summit ... annual meeting of the American Academy of Ophthalmology . ... 150 glaucoma patients in 6 countries by early 2015. ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 Punzoné ... introduced in the U.S., has a lot to celebrate this ... our country recognizes the achievements and contributions of Americans of ... anniversary for Punzoné, and today it shares its favorite Italian ... a trip to Italy - even if it is only ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 The ... iPage ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the ... excellent platforms for those who want to buy ... same time. , The IT manager of Top10BestSEOHosting.com ... the most recommended suppliers for everyone. A lot ...
(Date:10/19/2014)... Dr. Babatunde Osotimehin, Executive Director of ... a ceasefire agreement that is expected to lead to ... were kidnapped from the north-eastern Nigerian town of Chibok—the ... enough, and it is high time they are returned ... , "We owe it to these girls to positively ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2
... stem cell programs at respected research centers around the ... on stem cell therapy for neurological disorders, hosted by ... collaboration with the Genetics Policy Institute of Wellington, Fla. ... brain tumors; , stroke;, neurodegenerative disorders, , spinal cord ...
... Reporter , THURSDAY, April 28 (HealthDay News) -- More and ... and this means work-related injuries in this group continue to ... in the latest tally, federal health officials report. Although ... overall compared to younger workers, they are at higher risk ...
... 2011)Studies have shown that stress can affect the immune ... disease. In cancer patients this stress can also ... However, the biological mechanisms that underlie such associations are ... Center find that poor psychosocial functioning is associated with ...
... , THURSDAY, April 28 (HealthDay News) -- Memory ... a new study says. Experiments with rhesus monkeys showed ... Recognition is the ability to identify something when you see ... seen. The study appears online April 28 in the ...
... THURSDAY, April 28 (HealthDay News) -- Boceprevir, a new ... C is treated, won unanimous support Wednesday from a panel ... The drug is one of two new medications ... experts believe that, if approved, boceprevir and the second medicine, ...
... HealthDay Reporter , THURSDAY, April 28 (HealthDay News) -- ... while waiting to see their child,s pediatrician may aid ... recruited 137 pediatricians in the San Diego area to ... fill out before seeing the doctor. The test was ...
Cached Medicine News:Health News:Cedars-Sinai to hold first annual conference on stem cell therapies for neurological disorders 2Health News:Injuries Among Older Workers on the Rise: CDC 2Health News:Injuries Among Older Workers on the Rise: CDC 3Health News:Stress and depression are associated with shorter survival in head and neck cancer patients 2Health News:New Hepatitis C Drug Close to Gaining FDA Approval 2Health News:Quick Screening May Help Spot Autism in Babies 2Health News:Quick Screening May Help Spot Autism in Babies 3
... The ACL 10000 allows you to ... space and staff are limited. This fully ... clot curve analysis and advanced robotics, to ... lab. Plus, the ACL 10000 is backed ...
... SYNCHRON CX9 ALX system is an expanded ... processes by as much as 50 percent ... total costs. Featuring the AccuSense® glucose oxygen ... expanded test menu, the CX9 ALX system ...
... SYNCHRON CX4-S system consolidates DATs, ... in one workstation, targeted to ... 50-200 samples per day. Like ... the CX4-S is easy to ...
... a bold new way to improve your ... PRO. This expanded menu profiler eliminates time-consuming ... total turnaround time. Plus, the CX9 PRO ... esoteric chemistries, TDMs, DATs, proteins and serologies ...
Medicine Products: